News

Filtricine Presents Research at Scientific Conference for Cancer Treatment

Dr. Grace Xiaolu Yang
November 1, 2019

At the AACR-NCI-EORTC conference for molecular targets (#Targets19) at Boston, we presented our latest preclinical research on treating colon cancer and boosting anti-PD-1 immunotherapy with our “targeted nutrient deprivation” technology.

Latest News

Filtricine Preclinical Results Published

December 22, 2021
Filtricine is pleased to announce that the preclinical research results of its proprietary medical food technology
Read more

Clinical Results Presented at PCF Retreat

November 6, 2021
Filtricine is pleased to announce that researchers leading a Filtricine-sponsored prostate cancer clinical study at Stanford University
Read more

We Are Excited to Announce Filtricine's Latest Round of Investment

August 3, 2021
Filtricine's Seed Round announcement, led by Boutique Venture Partners and Berkeley Catalyst Fund
Read more

Filtricine Appoints a New Chief Executive Officer

December 22, 2020
It is our great pleasure to announce that Dr. John Chant has accepted our offer as Chief Executive Officer.
Read more

Filtricine Initiates the First Clinical Study

July 8, 2020
Filtricine today announced the start of its first human clinical study among prostate cancer patients.
Read more

IndieBio Demo Day Presentation

November 6, 2018
We proudly graduated from the phenomenal four-month program at IndieBio.
Read more
View all
We are a clinical-stage biotechnology company based in the San Francisco Bay Area dedicated to developing novel food products for disease control.
© 2022 Filtricine, Inc. All Rights Reserved | by Wuilt
Privacy PolicyTerms of use